Talvey, the blood cancer therapy, is crafted to unite cancer cells with immune cells, enabling the body's immune system to eliminate the cancer.

Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.